Patent intelligence · US
US 10532079
Extracts and beverages containing 2,5-piperazinedione, 3,6-bis(phenylmethyl)-, (3S,6S)-
Extracts and beverages containing 2,5-piperazinedione, 3,6-bis(phenylmethyl)-, (3S,6S)-
Patent details — US 10532079
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 14, 2020
- Expiration
- Jan 9, 2040
- Applicant
- SUNTORY BEVERAGE & FOOD ASIA PTE. LTD.
- Claims
- 10
- CPC classes
- A61K, A61K38/12, A61K9/0095, A61P
Quick answer
US 10532079 (Extracts and beverages containing 2,5-piperazinedione, 3,6-bis(phenylmethyl)-, (3S,6S)-) is held by SUNTORY BEVERAGE & FOOD ASIA PTE. LTD.. Status: granted. Granted Jan 14, 2020. Expires Jan 9, 2040 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SUNTORY BEVERAGE & FOOD ASIA PTE. LTD.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K38/12, A61K9/0095, A61P, A61P25/00, A61P25/24
More from SUNTORY BEVERAGE & FOOD ASIA PTE. LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12403164
Lentiviral vector formulations
granted -
US 12403183
Factor VIII polypeptide formulations
granted -
US 12391750
Anti-C1S antibodies and methods of use thereof
granted -
US 12371747
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
granted -
US 12364774
Nucleic acid molecules and uses thereof for non-viral gene therapy
granted -
US 12268688
Compositions and methods of use for modified release minoxidil
granted -
US 12257288
Methods of inducing immune tolerance to clotting factors
granted -
US 12240917
Anti-complement C1s antibodies and uses thereof
granted
Frequently asked questions
What is US patent 10532079?
US 10532079 (Extracts and beverages containing 2,5-piperazinedione, 3,6-bis(phenylmethyl)-, (3S,6S)-) is held by SUNTORY BEVERAGE & FOOD ASIA PTE. LTD.. Status: granted. Granted Jan 14, 2020. Expires Jan 9, 2040 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10532079?
SUNTORY BEVERAGE & FOOD ASIA PTE. LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 140 pharmaceutical patents for this assignee.
When does US 10532079 expire?
Our index shows an expiration date of Jan 9, 2040 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.